Clinical Trials
21 trialsNCT04484623 2026-06-12
DREAMM 8
GlaxoSmithKline
Phase 3 Active not recruiting
NCT07227311 2026-06-10
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
GlaxoSmithKline
Phase 2 Recruiting
NCT07614360 2026-05-29
DREAMM-16
GlaxoSmithKline
Phase 2 Not yet recruiting
NCT07609706 2026-05-27
A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment
GlaxoSmithKline
Phase 1 Not yet recruiting
NCT05714839 2026-05-22
DREAMM-20
GlaxoSmithKline
Phase 1/2 Recruiting
NCT05853965 2026-05-18
BELI(E)VE
Universitätsklinikum Hamburg-Eppendorf
Phase 1/2 Recruiting
NCT07285239 2026-05-18
PrE1005
PrECOG, LLC.
Phase 3 Not yet recruiting
NCT05002816 2026-05-13
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
Yale University
Phase 1/2 Active not recruiting
NCT05060627 2026-05-11
Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide
PETHEMA Foundation
Phase 1/2 Active not recruiting
NCT04126200 2026-05-06
DREAMM 5
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT07084896 2026-05-06
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT05064358 2026-05-05
DREAMM 14
GlaxoSmithKline
Phase 2 Completed
NCT02343042 2026-05-04
STOMP
Karyopharm Therapeutics Inc
Phase 1/2 Active not recruiting
NCT04246047 2026-04-23
DREAMM 7
GlaxoSmithKline
Phase 3 Active not recruiting
NCT06868654 2026-04-23
DREAMM 7
GlaxoSmithKline
Phase 3 Active not recruiting
NCT06868667 2026-04-23
DREAMM 7
GlaxoSmithKline
Phase 3 Active not recruiting
NCT06679101 2026-04-22
DREAMM-10
GlaxoSmithKline
Phase 3 Recruiting
NCT04822337 2026-04-16
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
Wake Forest University Health Sciences
Phase 1/2 Active not recruiting
NCT04162210 2026-03-31
DREAMM-3
GlaxoSmithKline
Phase 3 Active not recruiting
NCT04876248 2026-03-31
Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant
Roswell Park Cancer Institute
Phase 2 Active not recruiting
NCT06232044 2026-03-25
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
Alliance for Clinical Trials in Oncology
Phase 1/2 Recruiting